Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,730,881
  • Shares Outstanding, K 94,542
  • Annual Sales, $ 0 K
  • Annual Income, $ -408,170 K
  • EBIT $ -781 M
  • EBITDA $ -774 M
  • 60-Month Beta 1.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.71

Options Overview Details

View History
  • Implied Volatility 118.64% ( +3.22%)
  • Historical Volatility 52.11%
  • IV Percentile 87%
  • IV Rank 76.49%
  • IV High 138.64% on 05/24/24
  • IV Low 53.57% on 08/16/24
  • Put/Call Vol Ratio 2.00
  • Today's Volume 15
  • Volume Avg (30-Day) 2,443
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 44,261
  • Open Int (30-Day) 42,844

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.67
  • Number of Estimates 9
  • High Estimate -1.27
  • Low Estimate -2.02
  • Prior Year -1.50
  • Growth Rate Est. (year over year) -11.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.63 +2.98%
on 10/07/24
55.70 -10.10%
on 10/08/24
+2.44 (+5.13%)
since 10/04/24
3-Month
33.85 +47.93%
on 08/06/24
55.70 -10.10%
on 10/08/24
+15.85 (+46.29%)
since 08/05/24
52-Week
26.80 +86.85%
on 05/29/24
62.21 -19.51%
on 03/08/24
+19.26 (+62.48%)
since 11/03/23

Most Recent Stories

More News
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal

Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and safety of its investigational muscle-targeted...

BHVN : 50.15 (+0.22%)
ANIP : 56.25 (+0.43%)
CPRX : 21.60 (-0.69%)
SRRK : 27.20 (-1.70%)
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

Shares of Biohaven Ltd. BHVN were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for...

BHVN : 50.15 (+0.22%)
KRYS : 173.48 (+1.54%)
FULC : 3.28 (+0.61%)
ANIP : 56.25 (+0.43%)
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?

Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug.

BHVN : 50.15 (+0.22%)
Canada Jobs in Focus Next Week

Monday U.S. Featured Earnings Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (Q1) EPS of $3.66, ...

VRTX : 491.72 (+4.00%)
MCHP : 73.77 (-0.94%)
PLTR : 50.47 (+21.88%)
DIS : 96.27 (+0.50%)
ANET : 404.85 (+2.52%)
TM : 173.74 (+0.60%)
UBER : 73.77 (+0.71%)
ABNB : 140.03 (+2.31%)
HMC : 30.25 (-0.07%)
CEG : 229.59 (+1.61%)
RBLX : 49.78 (-0.44%)
BHVN : 50.15 (+0.22%)
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including...

BHVN : 50.15 (+0.22%)
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 50.15 (+0.22%)
Markets Today: Stocks Decline as Bond Yields Soar

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.61%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.76%. Stock index futures this morning are moderately lower, weighed...

ESZ24 : 5,784.25 (+0.71%)
NQZ24 : 20,275.00 (+0.94%)
MCK : 527.01 (+0.20%)
BHVN : 50.15 (+0.22%)
ABNB : 140.03 (+2.31%)
KLG : 16.62 (+0.97%)
HPQ : 36.27 (+0.78%)
DOW : 47.44 (-1.06%)
LYB : 83.48 (-0.84%)
FVRR : 28.92 (+2.70%)
DY : 182.23 (+3.58%)
PNT : 12.50 (+0.16%)
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 50.15 (+0.22%)
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 50.15 (+0.22%)
Why Biohaven Stock Is Skyrocketing Today

Promising clinical trial data led investors to bid the stock up, adding to its solid year-to-date gain.

BHVN : 50.15 (+0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut....

See More

Key Turning Points

3rd Resistance Point 52.75
2nd Resistance Point 51.69
1st Resistance Point 50.87
Last Price 50.15
1st Support Level 48.99
2nd Support Level 47.93
3rd Support Level 47.11

See More

52-Week High 62.21
Last Price 50.15
Fibonacci 61.8% 48.68
Fibonacci 50% 44.50
Fibonacci 38.2% 40.33
52-Week Low 26.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar